FYB1

Across TCGA pan-cancer cohorts, FYB1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FYB1 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FYB1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated FYB1 expression acts as an unfavorable survival marker, although some lineages such as LUAD and PDAC show a favorable association.

LUAD, PDAC, and HNSC are the cancer types where FYB1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	All	0.770	0.503	.002	15	view →
PDAC	DFS	Median	IV	0.934	0.250	.024	9	view →
HNSC	DFS	Quartile	II,III,IV	0.628	0.878	.028	7	view →
COAD	DFS	Quartile	III,IV	0.791	1.000	.049	6	view →
GBM	OS	Quartile	All	0.243	0.486	.021	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FYB1–LUAD (DFS)

Open the LUAD breakdown →